CompletedPhase 2NCT01406873
Clinical Efficacy Trial of Mexiletine for Myotonic Dystrophy Type 1
Studying Myotonic dystrophy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Rochester
- Principal Investigator
- Richard T. Moxley, III, MDUniversity of Rochester
- Intervention
- Mexiletine(drug)
- Enrollment
- 42 enrolled
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2011 – 2017
Study locations (1)
- University of Rochester Medical Center, Department of Neurology, Rochester, New York, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01406873 on ClinicalTrials.govOther trials for Myotonic dystrophy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07486934Efficacy, Safety, and Tolerability of DYNE-101 in Participants With Myotonic Dystrophy Type 1Dyne Therapeutics
- RECRUITINGPHASE2NCT07220603An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE)PepGen Inc
- ACTIVE NOT RECRUITINGNCT07493525Fall Frequency and Factors Affecting Dynamic Balance in Patients With Myotonic Dystrophy Type 1Antalya Training and Research Hospital
- RECRUITINGNCT06747884Trial Readiness and Endpoint Assessment in Pediatric Myotonic Dystrophy ExtensionVirginia Commonwealth University
- RECRUITINGNCT07385443The Spanish National Registry for Myotonic Dystrophy Type 1Fundació Institut Germans Trias i Pujol
- RECRUITINGNCT07362875Development of Quantitative Muscle Imaging as a Biomarker of Disease Endpoints in Myotonic DystrophyWake Forest University Health Sciences
- RECRUITINGNANCT06809049Music Intervention for Brain-Heart Disease in Myotonic Dystrophy Type 1 (DM1)Hanns Lochmuller
- RECRUITINGPHASE2NCT06667453A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1PepGen Inc